Price
Target price
€66.50
€66.50
2.310%
-
2.310%
€67.48
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Protagonist Therapeutics Inc Stock
There is an upward development for Protagonist Therapeutics Inc compared to yesterday, with an increase of €0.000 (2.310%).
With 26 Buy predictions and 1 Sell predictions Protagonist Therapeutics Inc is one of the favorites of our community.
At the moment Protagonist Therapeutics Inc has reached the predicted target price of 67 €, with a current price of 66.5 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Protagonist Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Protagonist Therapeutics Inc in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
Protagonist Therapeutics (NASDAQ:PTGX) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
News
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
Clinical-stage biotech Protagonist Therapeutics (NASDAQ: PTGX) was all the rage on the stock market Friday. The company's share price closed a dizzying 29.8% higher on the day, thanks to intense
Protagonist (PTGX) Q2 Revenue Falls 26%
Protagonist Therapeutics (NASDAQ:PTGX), a clinical-stage biotechnology company developing peptide-based therapies for blood and immune diseases, released second quarter results on August 6, 2025